Acute Myeloid Leukemia

Sorry, no news articles match your request. Your search criteria may be too narrow.

Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages.

The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Several risk factors and chromosomal abnormalities have been identified, but the specific cause is not clear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.

AML has several subtypes; treatment and prognosis varies among subtypes. Five-year survival varies from 15–70%, and relapse rate varies from 33-78%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. Recent research into the genetics of AML has resulted in the availability of tests that can predict which drug or drugs may work best for a particular patient, as well as how long that patient is likely to survive.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Dyslexia and sight: the wider view

There is widespread belief in the scientific community that dyslexia, which affects around 375,000 UK children and has a lifelong impact on learning, is not caused by sight problems. However, many practitioners ...

The coming merge of human and machine intelligence

For most of the past two million years, the human brain has been growing steadily. But something has recently changed. In a surprising reversal, human brains have actually been shrinking for the last 20,000 ...

How the brain makes decisions

Some types of decision-making have proven to be very difficult to simulate, limiting progress in the development of computer models of the brain. EPFL scientists have developed a new model of complex decision-making, ...